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Abstract
Background: Although the survival benefits of antiretroviral therapy (ART) for the treatment of HIV
infection are well established, the clinical management of HIV disease continues to present major
challenges. There are particular concerns regarding access to appropriate HIV treatment among HIV-
infected injection drug users (IDU).
Methods: In a prospective cohort study of HIV-infected IDU in Vancouver, Canada, we examined initial
ART regimens vis-à-vis the provincial government's therapeutic guidelines at the time ART was initiated.
Briefly, there have been four sets of guidelines: Era 1 (1992 to November 1995; double-drug (dual NRTIs)
ART for patients with a CD4 cell count of 350 or less); Era 2 (December 1995 to May 1996; double-drug
therapy for patients with a CD4+ cell count of 500 or less); Era 3 (June 1996 to June 1997; triple-drug
therapy (dual NRTIs with a PI or NNRTI) for patients who had a plasma viral load of > 100,000 HIV-1
RNA copies/mL; dual therapy with two NRTIs for those with a plasma viral load of 5,000 to 100,000 HIV-
1 RNA copies/mL); Era 4 (since July 1997; universal use of triple drug therapy as first-line treatment).
Results: Between May 1996 and May 2003, 431 HIV-infected individuals were enrolled into the cohort.
By May 31, 2003, 291 (67.5%) individuals had initiated ART. We noted instances of inappropriate
antiretroviral prescription in each guideline era, with 9 (53%) in Era 1, 3 (12%) in Era 2, 22 (28%) in Era 3,
and 23 (15%) in Era 4. Of the 57 subjects who received an inappropriate ART regimen initially, 14 never
received the appropriate therapy; among the remaining 43, the median time to the initiation of a guideline-
appropriate ART regimen was 12 months (inter-quartile range 5 – 20).
Conclusion: The present study identified measurable rates of guideline-inappropriate ART prescription
for patients who were injection drug users. Rates were highest in the era of dual therapy, although high
rates persisted into the triple-therapy era. As therapeutic guidelines continue to evolve, it is critical that
mechanisms be put in place to ensure prescription of ART combinations for IDU that are consistent with
current expert recommendations.
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Since the introduction of antiretroviral therapy (ART) in
the mid-1990s, the survival benefits of this treatment for
the management of HIV infection have been well estab-
lished [1-4]. Nevertheless, the clinical management of
HIV disease continues to present major challenges. Per-
sons undergoing treatment for HIV disease must follow a
daily regimen, known as highly active antiretroviral ther-
apy (HAART), consisting of at least three antiretroviral
drugs (i.e., two nucleoside reverse transcriptase inhibitors
[NRTIs] plus a protease inhibitor [PI] or a non-nucleoside
reverse transcriptase inhibitor [NNRTI]), and follow a
scheduled dosing protocol that often involves coordina-
tion of dietary intake [5]. Previous studies have demon-
strated that persons initially prescribed non-HAART
regimens consisting of only one or two antiretroviral
drugs have a lesser virologic response [19, 20], as well as
significantly shorter survival than persons who initiate
therapy with HAART [21, 22].
Since the advent of ART, there have been growing con-
cerns regarding access to HIV treatment among HIV-
infected injection drug users (IDU) [6,7]. Studies have
demonstrated that IDU may be less likely to receive ART,
even in settings where all HIV/AIDS care is provided free
of charge [8]. We have recently shown that in comparison
to non-injection drug users, IDU are more likely to be pre-
scribed non-HAART regimens, even after adjustment for
baseline clinical characteristics [9]. However, a compre-
hensive examination of the prevalence of inappropriate
ART prescription among injection drug users has not pre-
viously been conducted. We therefore examined the rate
of ART in a prospective cohort of HIV-infected injection
drug users and examined the prevalence of ART prescrip-
tions that were inappropriate, given the recommenda-
tions of therapeutic guidelines at the time ART was
initiated.
Methods
The Barriers to Antiretroviral Therapy (BART) cohort, a
prospective study of HIV-infected injection drug users
who have been recruited through self-referral and street
outreach from the Downtown Eastside of Vancouver,
Canada, since May 1996, has been described in detail pre-
viously [6,10]. Briefly, participants complete an inter-
viewer-administered questionnaire, are provided referral
to primary health care and addiction treatment where
available, and are provided a nominal stipend at each
study visit. Ethical approval has been annually provided
by the University of British Columbia's Research Ethics
Board. The BART cohort is unique in that it does not rely
on self-reported use of ART, since endpoints related to the
use of antiretroviral therapy can be accurately ascertained
through a confidential record linkage with the province's
centralized HIV/AIDS monitoring and treatment registry
which includes all patients receiving ART in the province
of British Columbia [6,10,11].
The primary endpoint of interest in the present analysis
was the content of the initial ART regimen, and we were
specifically interested in the rate of antiretroviral therapy
use that was inconsistent with the recommendations of
the province's therapeutic guidelines at the time antiretro-
viral therapy was initiated. The guidelines in the province
of British Columbia have been described in detail previ-
ously [2,12]. Briefly, between 1992 and November 1995
(Era 1), the guidelines made available double-NRTI
antiretroviral therapy for people with a CD4 cell count of
350 or less; between December 1995 and May 1996 (Era
2), double-NRTI therapy was made available to everyone
with a CD4+ cell count of 500 or less; between June 1996
and June 1997 (Era 3), antiretroviral therapy guidelines
based on plasma viral load were used, and individuals
who had a plasma viral load of > 100,000 HIV-1 RNA cop-
ies/mL were offered triple-drug regimens (i.e., HAART),
whereas those with a plasma viral load of 5,000 to
100,000 HIV-1 RNA copies/mL were offered dual NRTI
therapy; and in July 1997 (Era 4), the guidelines univer-
sally recommended the use of HAART as first-line treat-
ment.
Results
Between May 1996 and May 2003, 431 HIV infected indi-
viduals were enrolled into the BART cohort. Antiretroviral
use was subsequently prospectively and retrospectively
examined for these individuals through a confidential
record linkage with the province's centralized HIV/AIDS
treatment program, and it was determined that 291
(67.5%) individuals had initiated antiretroviral therapy
by May 31, 2003. Overall, 19 (6.9%) individuals had to
be excluded from subsequent analyses because baseline
plasma HIV RNA measures and/or baseline CD4 cell
count measures were unavailable.
Among the study sample of 272 individuals, the median
age of these participants was 36 (inter-quartile range: 30 –
42), 118 (43.4%) were female, and 115 (42.3%) reported
being of non-white race. Overall, 17 (6.3%) participants
initiated ART in Era 1, 26 (29.4%) in Era 2, 80 (29.4%) in
Era 3, and 149 (54.8%) in Era 4.
We noted that there were instances of inappropriate
antiretroviral prescription in each era, with 9 (53%) in Era
1, 3 (12%) in Era 2, 22 (28%) in Era 3, and 23 (15%) in
Era 4. In Eras 1 and 2, all inappropriate prescriptions
involved individuals being prescribed mono therapy
when they should have received dual therapy based on
their CD4 cell count. In Era 3, all inappropriate prescrip-
tions involved subjects who should have received triple
therapy based on their plasma HIV RNA but received dualPage 2 of 4
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when patients should have received triple therapy, 4
patients received single NNRTI therapy, 3 patients
received single NRTI therapy, 6 patients received dual
therapy with one NRTI and a PI or a NNRTI, and 10
patients received dual NRTI therapy. Overall, of the 57
subjects who received an incorrect ART prescription ini-
tially, 14 never received the correct number of drugs, and
among the remaining 43, the median time to the initia-
tion of a correct ART regimen was 12 months (inter-quar-
tile range 5 – 20). Interestingly, when we compared those
to received appropriate ART to those that received guide-
line-inappropriate ART, we found that no physician or
patient characteristics were associated with receiving inap-
propriate therapy.
Discussion
In the present study, we documented measurable rates of
ART prescription that were inconsistent with the recom-
mendations of the therapeutic guidelines that were in
place at the time that ART was initiated. Our findings may
be explained by the difficulty some physicians may have
had in keeping up with changes in HIV therapeutic guide-
lines and by the fact that inappropriate prescriptions com-
monly resulted from lack of knowledge about the change
in guidelines [9]. In addition, limited access to appropri-
ate ART combinations among persons with a history of
injection drug use may reflect the belief of some physi-
cians that persons with less stable lifestyles may have bet-
ter adherence to a less complex regimen [7,13]. Finally, it
is also possible that concerns regarding possible transmis-
sion of PI- or NNRTI-resistant virus influenced prescribing
decisions [14,15].
With regard to the above, it is noteworthy that a recent
study demonstrated that a substantial proportion of
homeless and marginally housed individuals had good
adherence to antiretroviral therapy including protease
inhibitors, and that resistance to PIs was rare among those
who were non-adherent [25]. Furthermore, it was recently
argued that physicians should not indefinitely withhold
ART from patients who are thought to be poorly adherent
[26], and studies have shown that providers may be poor
judges of adherence [27]. The present study demonstrates
the high rate of inappropriate ART prescription but is lim-
ited in its ability to explain why measurable numbers of
IDU received incorrect HAART regimens. Future studies
should examine physician and patient reasons for select-
ing specific ART regimens. Studies are also needed to
examine ways to ensure physician compliance with thera-
peutic guidelines since it is likely that HIV therapies will
continue to be multi-drug, and that therapeutic guidelines
will continue to evolve rapidly [16]. In our own setting
where HAART delivery is centralized, systems are now in
place to ensure all prescriptions are consistent with cur-
rent therapeutic guidelines.
Conclusion
In the present study, we documented measurable rates of
inappropriate ART prescribing patterns among injection
drug users. Rates were highest in the era of dual therapy,
although high rates persisted into the era of HAART. Since
HIV therapeutic guidelines will likely continue to evolve
as novel agents become available and additional informa-
tion about ART benefits and toxicities arises, it is critical
that mechanisms be put in place to ensure that physicians
are providing ART combinations that are up-to-date with
current knowledge.
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